GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2012

CHDI, Lundbeck Partner for Preclinical Studies with Huntington Disease Candidate

  • CHDI Foundation is teaming up with Lundbeck to aid preclinical development of the latter’s Huntington disease (HD) therapeutic candidate. In particular, the studies will assess the compound's effects on P2X receptors implicated in the disease.

    Lundbeck says the partnership fits in with its HD Research Initiative, launched in 2010, through which the firm is working with academic groups, research organizations, and other companies to develop new therapeutic approaches to HD. The Initiative includes a collaboration the University of Massachusetts Medical School to investigate RNAi-based therapies that suppress production of the mutant huningtin protein responsible for HD.

    Lundbeck is focused on the development of treatments for a range of CNS disorders including depression, anxiety, schizophrenia, epilepsy, Alzheimer disease, and Parkinson disease. The firm’s Xenazine® is the only FDA-approved drug indicated for reducing chorea associated with HD. Xenazine achieved sales of DKK 281 million (about $48.2 million) in the first quarter of 2012, an increase of 35% over the same quarter in 2011.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »